
Semax
- Evidence
- Limited research
- Class
- Nootropic peptide (ACTH(4-10) analog)
Semax belongs to the Nootropic peptide (ACTH(4-10) analog) class. This library groups it under brain & sleep. Its source category is Not FDA-approved.
At a glance
| Compound class | Nootropic peptide (ACTH(4-10) analog) |
|---|---|
| Body system | Brain & sleep |
| Use or research focus | Cognition, neuroprotection |
| Regulatory status | Not FDA-approved; PCAC voted favorably (Jul 2026) for 503A compounding — final FDA rule pending |
| Source evidence rating | Limited research |
How does Semax work?
Raises BDNF/neurotrophic signaling.
The source catalog maps this mechanism to Brain / CNS. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Semax?
Semax belongs to the Nootropic peptide (ACTH(4-10) analog) class. This library groups it under brain & sleep. Its source category is Not FDA-approved. Its recorded use or research focus is: Cognition, neuroprotection.
Is Semax FDA-approved?
The catalog records: Not FDA-approved; PCAC voted favorably (Jul 2026) for 503A compounding — final FDA rule pending. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 12 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for brain & sleep
Factual catalog fields and citation links are adapted from Superpower’s Semax guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Semax in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01studiesdoi.org
- 02FDA staff opposed it citing insufficient evidencestatnews.com
- 03analytical reviewdoi.org
- 04BDNF and NGFdoi.org
- 05registration as a drug in Russiafda.gov
- 06ischemic stroke rehabilitationpubmed.ncbi.nlm.nih.gov
- 07chronic cerebrovascular insufficiencypubmed.ncbi.nlm.nih.gov
- 08optic nerve diseasepubmed.ncbi.nlm.nih.gov
- 09boosted serotonin activity and amplified amphetamine-driven dopamine releasedoi.org
- 10resting-state fMRI studypubmed.ncbi.nlm.nih.gov
- 111997 comparative study in acute ischemic strokepubmed.ncbi.nlm.nih.gov
- 12in Category 1fda.gov





